Proposed Data Collections Submitted for Public Comment and Recommendations, 19853-19854 [E8-7706]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 71 / Friday, April 11, 2008 / Notices
including low- and moderate-income
neighborhoods, consistent with the safe
and sound operation of the institution.
12 U.S.C. § 2903.
mstockstill on PROD1PC66 with NOTICES
Procedures for Hearing
Testimony at the public meetings will
be presented to a panel consisting of a
Presiding Officer and other panel
members appointed by the Presiding
Officer. In conducting the public
meetings, the Presiding Officer will
have the authority and discretion to
ensure that the meetings proceed in a
fair and orderly manner. In contrast to
a formal administrative hearing, the
rules for taking evidence will not apply
to the public meetings. Panel members
may question witnesses but no crossexamination of witnesses will be
permitted. The public meetings will be
transcribed, and the transcripts will be
posted on the Board’s public website
within several days after the meetings.
Information regarding the procedures
for obtaining a copy of the transcript
will be announced at the public
meetings.
On the basis of the requests received,
the Presiding Officer will prepare a
schedule for participants who will
testify and establish the order of
presentation. To ensure an opportunity
for all interested commenters to present
their views, the Presiding Officer may
limit the time for presentation.
Individuals not listed on the schedule
may be permitted to speak at the public
meeting if time permits at the
conclusion of the schedule of witnesses,
at the discretion of the Presiding Officer.
Copies of testimony may, but need not,
be filed with the Presiding Officer
before a participant’s presentation.
Request To Testify
All persons wishing to testify at the
public meeting to be held in Los
Angeles must submit a written request
to Scott Turner, Community Affairs
Officer, Federal Reserve Bank of San
Francisco, 101 Market Street, San
Francisco, California 94105 (facsimile:
415/393–1920) no later than 5 p.m. PDT
on April 15, 2008. All persons wishing
to testify at the public meeting to be
held in Chicago must submit a written
request to Alicia Williams, Vice
President, Federal Reserve Bank of
Chicago, 230 South LaSalle Street,
Chicago, Illinois 60604 (facsimile: 312/
913–2626) no later than 5 p.m. CDT on
April 15, 2008.
The request to testify must include
the following information: (i)
Identification of which meeting (and
which day for the Los Angeles meeting)
the participant wishes to attend; (ii) a
brief statement of the nature of the
VerDate Aug<31>2005
19:21 Apr 10, 2008
Jkt 214001
expected testimony (including whether
the testimony will support or oppose
the proposed transaction or provide
other comment on the proposal) and the
estimated time required for the
presentation; (iii) the address and
telephone number (and e-mail address
and facsimile number, if available) of
the individual testifying; and (iv)
identification of any special needs, such
as individuals needing translation
services, individuals with a physical
disability who may need assistance, or
individuals requiring visual aids for
their presentation. To the extent
available, translators will be provided
for those wishing to present their views
in a language other than English if so
requested in the request to testify.
Individuals interested only in attending
the meeting, but not testifying, need not
submit a written request.
By order of the Board of Governors of the
Federal Reserve System, effective April 8,
2008.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E8–7758 Filed 4–10–08; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–08–0010]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Maryam I. Daneshvar,
CDC Acting Reports Clearance Officer,
1600 Clifton Road, MS–D74, Atlanta,
GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
19853
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
The National Birth Defects Prevention
Study (NBDPS), (OMB 0920–0010)—
Extension—National Center on Birth
Defects and Developmental Disabilities
(NCBDDD), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
CDC has been monitoring the
occurrence of serious birth defects and
genetic diseases in Atlanta since 1967
through the Metropolitan Atlanta
Congenital Defects Program (MACDP).
The MACDP is a population-based
surveillance system for birth defects in
the 5 counties of Metropolitan Atlanta.
Its primary purpose is to describe the
spatial and temporal patterns of birth
defects occurrence and serves as an
early warning system for new
Teratogens. In 1997, the Birth Defects
Risk Factor Surveillance (BDRFS) study,
a case-control study of risk factors for
selected birth defects, became the
National Birth Defects Prevention Study
(NBDPS). The major components of the
study did not change.
The NBDPS is a case-control study of
major birth defects that includes cases
identified from existing birth defect
surveillance registries in nine states,
including metropolitan Atlanta. Control
infants are randomly selected from birth
certificates or birth hospital records.
Mothers of case and control infants are
interviewed using a computer-assisted
telephone interview. The interview is
estimated to take one hour. A maximum
of four hundred interviews are planned,
300 cases and 100 controls resulting in
a maximum interview burden of 400
hours for each of the Centers.
Parents are also asked to collect cheek
cells from themselves and their infants
for DNA testing. The collection of cheek
cells by the mother, father, and infant is
estimated to take about 10 minutes per
person. Each person will be asked to rub
1 brush inside the left cheek and 1
brush inside the right cheek for a total
of 2 brushes per person. Collection of
the cheek cells takes approximately 1–
2 minutes, but the estimate of burden is
10 minutes to account for reading and
understanding the consent form and
specimen collection instructions and
mailing back the completed kits. The
anticipated maximum burden for
E:\FR\FM\11APN1.SGM
11APN1
19854
Federal Register / Vol. 73, No. 71 / Friday, April 11, 2008 / Notices
collection of the cheek cells is 200
hours.
Information gathered from both the
interviews and the DNA specimens will
be used to study independent genetic
and environmental factors as well as
gene-environment interactions for a
broad range of carefully classified birth
defects.
This request is submitted to obtain
OMB clearance for three additional
years.
There are no costs to the respondents
other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Number of
respondents
Respondents
Avg. burden
per response
(in hours)
Total burden
hours
NBDPS case/control interview .........................................................................
400
1
1
400
Biologic Specimen Collection ..........................................................................
1,200
1
10/60
200
Total ..........................................................................................................
........................
........................
........................
600
Dated: April 3, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E8–7706 Filed 4–10–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–R–263]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS) is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects:
(1) The necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions; (2) the accuracy of the
estimated burden; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Site
Investigation for Durable Medical
Equipment (DME) Suppliers; Use: The
Centers for Medicare and Medicaid
mstockstill on PROD1PC66 with NOTICES
AGENCY:
VerDate Aug<31>2005
19:21 Apr 10, 2008
Jkt 214001
Services (CMS) enrolls durable medical
equipment, prosthetics, orthotics, and
supplies (DMEPOS) suppliers into the
Medicare program via a uniform
application, the CMS 855S.
Implementation of enhanced procedures
for verifying the enrollment information
has improved the enrollment process as
well as identified and prevented
fraudulent DMEPOS suppliers from
entering the Medicare program. As part
of this process, verification of
compliance with supplier standards is
necessary. The site investigation form
has been used in the past to aid the
Medicare contractor (the National
Supplier Clearinghouse (NSC) and/or its
subcontractors) in verifying compliance
with the required supplier standards
found in 42 CFR 424.57(c). The primary
function of the site investigation form is
to provide a standardized, uniform tool
to gather information from a DMEPOS
supplier that tells us whether it meets
certain qualifications to be a DMEPOS
supplier (as found in 42 CFR 424.57(c))
and where it practices or renders its
services. Form Number: CMS–R–263
(OMB# 0938–0749); Frequency:
Occasionally; Affected Public: Business
or other for-profit and not-for-profit
institutions; Number of Respondents:
30,000; Total Annual Responses:
30,000; Total Annual Hours: 15,000.
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web site
address at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or Email your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
In commenting on the proposed
information collections please reference
the document identifier or OMB control
number. To be assured consideration,
comments and recommendations must
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
be submitted in one of the following
ways by June 10, 2008:
1. Electronically. You may submit
your comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) accepting comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number ___, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
Dated: April 4, 2008.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E8–7709 Filed 4–10–08; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Administration for Native Americans
Administration for Native
Americans, ACF, HHS.
ACTION: Notice to Award Urgent Grants.
AGENCY:
CFDA #: 93.612.
Legislative Authority: This award will
be made pursuant to Section 803 of the
Native American Programs Act of 1974.
Amount of Award: Six awards for a
total of $649,404.
Project Period: Up to six months.
SUMMARY: This notice is to inform the
public that the Administration for
Native Americans (ANA) intends to
announce six (6) urgent grant awards.
The urgent grant awards will fund
E:\FR\FM\11APN1.SGM
11APN1
]]>Agencies
[Federal Register Volume 73, Number 71 (Friday, April 11, 2008)]
[Notices]
[Pages 19853-19854]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-7706]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-08-0010]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960
and send comments to Maryam I. Daneshvar, CDC Acting Reports Clearance
Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail
to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
The National Birth Defects Prevention Study (NBDPS), (OMB 0920-
0010)--Extension--National Center on Birth Defects and Developmental
Disabilities (NCBDDD), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
CDC has been monitoring the occurrence of serious birth defects and
genetic diseases in Atlanta since 1967 through the Metropolitan Atlanta
Congenital Defects Program (MACDP). The MACDP is a population-based
surveillance system for birth defects in the 5 counties of Metropolitan
Atlanta. Its primary purpose is to describe the spatial and temporal
patterns of birth defects occurrence and serves as an early warning
system for new Teratogens. In 1997, the Birth Defects Risk Factor
Surveillance (BDRFS) study, a case-control study of risk factors for
selected birth defects, became the National Birth Defects Prevention
Study (NBDPS). The major components of the study did not change.
The NBDPS is a case-control study of major birth defects that
includes cases identified from existing birth defect surveillance
registries in nine states, including metropolitan Atlanta. Control
infants are randomly selected from birth certificates or birth hospital
records. Mothers of case and control infants are interviewed using a
computer-assisted telephone interview. The interview is estimated to
take one hour. A maximum of four hundred interviews are planned, 300
cases and 100 controls resulting in a maximum interview burden of 400
hours for each of the Centers.
Parents are also asked to collect cheek cells from themselves and
their infants for DNA testing. The collection of cheek cells by the
mother, father, and infant is estimated to take about 10 minutes per
person. Each person will be asked to rub 1 brush inside the left cheek
and 1 brush inside the right cheek for a total of 2 brushes per person.
Collection of the cheek cells takes approximately 1-2 minutes, but the
estimate of burden is 10 minutes to account for reading and
understanding the consent form and specimen collection instructions and
mailing back the completed kits. The anticipated maximum burden for
[[Page 19854]]
collection of the cheek cells is 200 hours.
Information gathered from both the interviews and the DNA specimens
will be used to study independent genetic and environmental factors as
well as gene-environment interactions for a broad range of carefully
classified birth defects.
This request is submitted to obtain OMB clearance for three
additional years.
There are no costs to the respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Avg. burden
Respondents Number of responses per per response Total burden
respondents respondent (in hours) hours
----------------------------------------------------------------------------------------------------------------
NBDPS case/control interview.................... 400 1 1 400
---------------------------------------------------------------
Biologic Specimen Collection.................... 1,200 1 10/60 200
---------------------------------------------------------------
Total....................................... .............. .............. .............. 600
----------------------------------------------------------------------------------------------------------------
Dated: April 3, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E8-7706 Filed 4-10-08; 8:45 am]
BILLING CODE 4163-18-P
